G1 Therapeutics announces publication on real world impact of trilaciclib

G1 Therapeutics announced the publication of real world outcomes data from published and new unpublished studies showing the potential of trilaciclib to reduce single and multilineage myelosuppressive events associated with chemotherapy, cytopenia-related healthcare utilization, and hospitalizations in adults being treated for extensive stage small cell lung cancer. This review of real-world experience with trilaciclib was published in Advanced Therapy. The publication, entitled, “Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy,” was the result of a comprehensive literature review and synthesized published and new unpublished real-world studies of trilaciclib-treated and comparable non-trilaciclib-treated patients with ES-SCLC. Outcomes were compared qualitatively between the trilaciclib and historical non-trilaciclib reference groups, and between first line trilaciclib initiators and the overall trilaciclib population. Existing real-world studies in ES-SCLC consistently demonstrate that trilaciclib-treated patients had numerically lower prevalence of single and multilineage gradegreater than or equal to3 myelosuppressive HAEs and lower cytopenia-related healthcare utilization, in reference to comparable historical non-trilaciclib cohorts. The real-world outcomes associated with trilaciclib are consistent with clinical trials, despite a higher proportion of elderly population, poorer performance status, and variation in timing of initiation of trilaciclib in real-world studies. In all trilaciclib cohorts, the weighted average prevalence of gradegreater than or equal to3 myelosuppressive HAEs in greater than or equal to1 lineage,greater than or equal to2 lineages, and all three lineages was 40.5%, 14.5%, and 7.5%, respectively. All rates were numerically lower compared to the historical non-trilaciclib cohorts. Cytopenia-related healthcare utilization was lower in the trilaciclib cohorts. Trilaciclib patients also had numerically fewer all-cause hospitalizations and shorter length of stay in reference to the historical non-trilaciclib patients. In general, first-line trilaciclib initiators had numerically even lower myelosuppressive HAEs and also lower cytopenia-related healthcare utilization than the overall trilaciclib patients. Dose reduction and treatment delay were also evaluated in certain of the reviewed studies. Lower average rates of dose reduction and treatment delays were observed among patients receiving trilaciclib in reference to the historical non-trilaciclib cohorts.